Patient-reported Outcome After Corticoid Injection for Triggerfinger- a Randomized Controlled Study Between Two Injection Procedures and Between Corticoid Injection and Percutaneous Release
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Impairment of finger motion
Study Overview
Brief Summary
This is a prospective randomized multicenterstudy focusing on PROMs after primary corticoid injection for triggerfinger with a comparison of two different injection techniques.
Detailed Description
This study aims to compare two different methods of corticosteroid injections in patients with triggerfinger, and to study the effects of these injections by day-to-day self-assessment by the included study persons for four weeks. The patient assess: 1. Pain 2. Motion and 3. Triggering by VAS scale every day for four weeks.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Triggering of one or more fingers and/or impaired active finger motion and/or pain during active finger motion
- •Localized tenderness volar to the MCP joint of the affected finger
- •The patient seeks treatment
Exclusion Criteria
- •Previous treatment for triggerfinger in the finger to be treated
- •Impaired function of finger due to previous trauma/infection or other condition
- •Suspicion of other cause than triggeriinger/tendovaginitis
- •Patient not able to follow instructions
Arms & Interventions
proximal phalangeal level
injection in the the tendon sheet over proximal phalanx of finger
Intervention: Proximal phalangeal level (Procedure)
volar MCP level
injection above the A1 pulley volar to the MCP joint
Intervention: Volar to the MCP-joint (Drug)
Outcomes
Primary Outcomes
Impairment of finger motion
Time Frame: Four weeks
Visual analouge scale (VAS), range 0-10, where 0 indicates "no impairment" and 10 "maximum impairment"
Triggering
Time Frame: Four weeks
Visual analouge scale (VAS), range 0-10, where 0 indicates "no trigger phenomenon" and 10 "Trigger phenomenon all the time/ locked finger"
Pain after injection
Time Frame: Four weeks
Visual analouge scale (VAS), range 0-10, where 0 indicates "no pain" and 10 "maximum pain"
Secondary Outcomes
- Quick-DASH(Four weeks)
Investigators
Joakim Stromberg
Senior consultant surgeon, MD, PhD
Sahlgrenska University Hospital